Literature DB >> 29269520

Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

Laurence Lodé1,2,3,4, Audrey Ménard2, Laurent Flet5, Steven Richebourg6, Marion Loirat7, Marion Eveillard2, Yannick Le Bris2, Catherine Godon2, Olivier Theisen2, Anne-Laure Gagez8, Guillaume Cartron3,8, Thérèse Commes-Maerten4, Bruno Villemagne9, Odile Luycx10, Pascal Godmer11, Catherine Pellat-Deceunynck12, Thierry Soussi13, Marie C Béné14, Jacques Delaunay7,15, Pierre Peterlin7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29269520      PMCID： PMC5865441          DOI： 10.3324/haematol.2017.181404

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Authors:  Martin Jädersten; Leonie Saft; Alexander Smith; Austin Kulasekararaj; Sabine Pomplun; Gudrun Göhring; Anette Hedlund; Robert Hast; Brigitte Schlegelberger; Anna Porwit; Eva Hellström-Lindberg; Ghulam J Mufti
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Clonal architecture of secondary acute myeloid leukemia.

Authors:  Matthew J Walter; Dong Shen; Li Ding; Jin Shao; Daniel C Koboldt; Ken Chen; David E Larson; Michael D McLellan; David Dooling; Rachel Abbott; Robert Fulton; Vincent Magrini; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Xian Fan; Marcus Grillot; Sarah Witowski; Sharon Heath; John L Frater; William Eades; Michael Tomasson; Peter Westervelt; John F DiPersio; Daniel C Link; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Timothy A Graubert
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Scott L Carter; Petar Stojanov; Aaron McKenna; Kristen Stevenson; Michael S Lawrence; Carrie Sougnez; Chip Stewart; Andrey Sivachenko; Lili Wang; Youzhong Wan; Wandi Zhang; Sachet A Shukla; Alexander Vartanov; Stacey M Fernandes; Gordon Saksena; Kristian Cibulskis; Bethany Tesar; Stacey Gabriel; Nir Hacohen; Matthew Meyerson; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  Cell       Date:  2013-02-14       Impact factor: 41.582

5.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

6.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

7.  Persistent malignant stem cells in del(5q) myelodysplasia in remission.

Authors:  Ramin Tehranchi; Petter S Woll; Kristina Anderson; Natalija Buza-Vidas; Takuo Mizukami; Adam J Mead; Ingbritt Astrand-Grundström; Bodil Strömbeck; Andrea Horvat; Helen Ferry; Rakesh Singh Dhanda; Robert Hast; Tobias Rydén; Paresh Vyas; Gudrun Göhring; Brigitte Schlegelberger; Bertil Johansson; Eva Hellström-Lindberg; Alan List; Lars Nilsson; Sten Eirik W Jacobsen
Journal:  N Engl J Med       Date:  2010-09-09       Impact factor: 91.245

Review 8.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

9.  Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.

Authors:  Christian Scharenberg; Valentina Giai; Andrea Pellagatti; Leonie Saft; Marios Dimitriou; Monika Jansson; Martin Jädersten; Alf Grandien; Iyadh Douagi; Donna S Neuberg; Katarina LeBlanc; Jacqueline Boultwood; Mohsen Karimi; Sten Eirik W Jacobsen; Petter S Woll; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

10.  Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.

Authors:  Maximilian Mossner; Johann-Christoph Jann; Janina Wittig; Florian Nolte; Stephanie Fey; Verena Nowak; Julia Obländer; Jovita Pressler; Iris Palme; Christina Xanthopoulos; Tobias Boch; Georgia Metzgeroth; Henning Röhl; Stephanie H Witt; Helene Dukal; Corinna Klein; Steffen Schmitt; Patrick Gelß; Uwe Platzbecker; Ekaterina Balaian; Alice Fabarius; Helmut Blum; Torsten J Schulze; Manja Meggendorfer; Claudia Haferlach; Andreas Trumpp; Wolf-Karsten Hofmann; Hind Medyouf; Daniel Nowak
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113
View more
  8 in total

1.  Getting personal with myelodysplastic syndromes: is now the right time?

Authors:  Nora Chokr; Alexander B Pine; Jan Philipp Bewersdorf; Rory M Shallis; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2019-04-12       Impact factor: 2.929

Review 2.  Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Authors:  Max Jan; Adam S Sperling; Benjamin L Ebert
Journal:  Nat Rev Clin Oncol       Date:  2021-03-02       Impact factor: 66.675

Review 3.  BMT for Myelodysplastic Syndrome: When and Where and How.

Authors:  Akriti G Jain; Hany Elmariah
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

4.  Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States.

Authors:  Abhay Singh; Megan M Herr; Elizabeth A Griffiths; Amanda Przespolewski; Mark G Faber; Chebli Mrad; Eunice S Wang; Theresa Hahn; Swapna Thota
Journal:  Sci Rep       Date:  2021-12-02       Impact factor: 4.379

Review 5.  Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration.

Authors:  Tzu-Hua Chen-Liang
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

6.  Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.

Authors:  Tarek H Mouhieddine; Adam S Sperling; Robert Redd; Jihye Park; Matthew Leventhal; Christopher J Gibson; Salomon Manier; Amin H Nassar; Marzia Capelletti; Daisy Huynh; Mark Bustoros; Romanos Sklavenitis-Pistofidis; Sabrin Tahri; Kalvis Hornburg; Henry Dumke; Muhieddine M Itani; Cody J Boehner; Chia-Jen Liu; Saud H AlDubayan; Brendan Reardon; Eliezer M Van Allen; Jonathan J Keats; Chip Stewart; Shaadi Mehr; Daniel Auclair; Robert L Schlossman; Nikhil C Munshi; Kenneth C Anderson; David P Steensma; Jacob P Laubach; Paul G Richardson; Jerome Ritz; Benjamin L Ebert; Robert J Soiffer; Lorenzo Trippa; Gad Getz; Donna S Neuberg; Irene M Ghobrial
Journal:  Nat Commun       Date:  2020-06-12       Impact factor: 14.919

Review 7.  TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings.

Authors:  Cosimo Cumbo; Giuseppina Tota; Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Francesco Albano
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

Review 8.  Current challenges and unmet medical needs in myelodysplastic syndromes.

Authors:  Uwe Platzbecker; Anne Sophie Kubasch; Collin Homer-Bouthiette; Thomas Prebet
Journal:  Leukemia       Date:  2021-05-28       Impact factor: 11.528
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.